Luye Pharma Group ( (LYPHF) ) has released its Q2 earnings. Here is a breakdown of the information Luye Pharma Group presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Luye Pharma Group Ltd. is an international pharmaceutical company specializing in the research, development, manufacturing, and sale of innovative medications, with a focus on oncology, central nervous system, cardiovascular, and metabolism therapeutic areas. The company operates in over 80 countries, including major markets such as China, the U.S., Europe, and Japan.
In its latest earnings report for the first half of 2025, Luye Pharma Group reported a 3.5% increase in revenue, reaching RMB3,181.1 million. However, the company faced a decline in net profit by 18.4% to RMB357.4 million, with profit attributable to shareholders also decreasing by 19.3% to RMB312.9 million. Despite these challenges, the company’s EBITDA saw a 4.2% increase, amounting to RMB1,204.2 million.
Key financial highlights include a gross profit increase of 3.8% to RMB2,157.6 million, with a gross profit margin of 67.8%. The company did not propose an interim dividend for the period. The earnings per share decreased from RMB10.31 cents to RMB8.32 cents. Luye Pharma’s revenue growth was primarily driven by its oncology and CNS therapeutic areas, which saw increases of 13.5% and 5.4%, respectively.
Looking ahead, Luye Pharma Group remains committed to its innovation-driven and internationalization strategies. The company continues to invest in research and development across its four strategic therapeutic areas, with a robust pipeline of drug candidates in various stages of development. Luye Pharma’s management is optimistic about maintaining its competitive position in the global pharmaceutical market.